MORRISVILLE, N.C.--(BUSINESS WIRE)--Tenax Therapeutics, Inc. (NASDAQ: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today announced financial results for the third quarter ended September 30, 2016, and provided a corporate update.
“We are pleased to be enrolling our last patients in the Phase 3 LEVO-CTS trial, after which we will begin preparing to lock our database,” said John Kelley, CEO of Tenax Therapeutics. “We currently expect top-line data for the trial to readout in January 2017. This is the largest study ever conducted for levosimendan in the LCOS indication and we believe that our drug has the potential to provide an important treatment option for this critical care population. The growing interest and participation in LEVO-CTS confirms the significant commercial opportunity in North America and we are prepared to move forward with an NDA submission and subsequent product launch if this data is positive. We look forward to sharing these results with you shortly.”
